Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liquidambar styraciflua pollen is an allergenic extract derived from the pollen of the sweetgum tree (Liquidambar styraciflua). [18] It is used for both the diagnosis and treatment of individuals with immediate hypersensitivity allergies to this specific pollen. [22] As a non-standardized pollen allergenic extract, it functions as a form of immunotherapy (allergy shots) to desensitize the immune system. [17] The treatment is intended to modulate the body's immune response, encouraging a shift from an allergic IgE-dominant reaction to a tolerance-based state characterized by increased production of IgG antibodies. [17, 22] This reduces the release of histamine and other mediators that cause allergy symptoms. [17, 22] It is administered via percutaneous, intradermal, or subcutaneous injection for skin testing and hyposensitization. The product, first approved in the U.S. in 1965, is marketed by companies such as ALK-Abello and Stallergenes Greer. [19]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liquidambar styraciflua pollen.